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A B S T R A C T
Background
The tendency for authors to submit, and of journals to accept, manuscripts for publication based on the direction or strength of the
study findings has been termed publication bias.
Objectives
To assess the extent to which publication of a cohort of clinical trials is influenced by the statistical significance, perceived importance,
or direction of their results.
Search methods
We searched the Cochrane Methodology Register (The Cochrane Library [Online] Issue 2, 2007), MEDLINE (1950 to March Week
2 2007), EMBASE (1980 to Week 11 2007) and Ovid MEDLINE In-Process & Other Non-Indexed Citations (March 21 2007). We
also searched the Science Citation Index (April 2007), checked reference lists of relevant articles and contacted researchers to identify
additional studies.
Selection criteria
Studies containing analyses of the association between publication and the statistical significance or direction of the results (trial
findings), for a cohort of registered clinical trials.
Data collection and analysis
Two authors independently extracted data. We classified findings as either positive (defined as results classified by the investigators as
statistically significant (P < 0.05), or perceived as striking or important, or showing a positive direction of effect) or negative (findings
that were not statistically significant (P ≥ 0.05), or perceived as unimportant, or showing a negative or null direction in effect). We
extracted information on other potential risk factors for failure to publish, when these data were available.
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Main results
Five studies were included. Trials with positive findings were more likely to be published than trials with negative or null findings (odds
ratio 3.90; 95% confidence interval 2.68 to 5.68). This corresponds to a risk ratio of 1.78 (95% CI 1.58 to 1.95), assuming that 41%
of negative trials are published (the median among the included studies, range = 11% to 85%). In absolute terms, this means that if
41% of negative trials are published, we would expect that 73% of positive trials would be published.
Two studies assessed time to publication and showed that trials with positive findings tended to be published after four to five years
compared to those with negative findings, which were published after six to eight years. Three studies found no statistically significant
association between sample size and publication. One study found no significant association between either funding mechanism,
investigator rank, or sex and publication.
Authors’ conclusions
Trials with positive findings are published more often, and more quickly, than trials with negative findings.
P L A I N L A N G U A G E S U M M A R Y
Publication bias in clinical trials due to statistical significance or direction of trial results
The validity of a systematic review depends on the methods used to conduct the review. If there is a systematic bias, such that studies
with statistically significant or positive findings are more likely to be published and included in systematic reviews than trials with non-
significant findings, then the validity of a review’s conclusions can be threatened.
This methodology review identified five studies that investigated the extent to which the publication of clinical trials (such as those
approved by an ethics review board) is influenced by the statistical significance or direction of a trial’s results. These studies showed
that trials with positive findings (defined either as those that were statistically significant (P < 0.05), or those findings perceived to be
important or striking, or those indicating a positive direction of treatment effect), had nearly four times the odds of being published
compared to findings that were not statistically significant (P ≥ 0.05), or perceived as unimportant, or showing a negative or null
direction of treatment effect. This corresponds to a risk ratio of 1.78 (95% CI 1.58 to 1.95), assuming that 41% of negative trials
are published.Two studies found that trials with positive findings also tended to be published more quickly than trials with negative
findings. The size of the trial (assessed in three studies) and the source of funding, academic rank, and sex of the principal investigator
(assessed in one study) did not appear to influence whether a trial was published.
These results provide support for mandating that clinical trials are registered before recruiting participants so that review authors know
about all potentially eligible studies, regardless of their findings. Those carrying out systematic reviews should ensure they assess the
potential problems of publication bias in their review and consider methods for addressing this issue by ensuring a comprehensive
search for both published and unpublished trials.
B A C K G R O U N D
Completed research is frequently left unpublished (Dickersin
1990). It has been suggested that in the case of research conducted
on humans, failure to publish represents scientific misconduct,
since individuals who consent to participate in research, and agen-
cies that provide funding support for these investigations, do so
with the understanding that the work will make a contribution to
knowledge (Chalmers 1990). Clearly, knowledge that is not dis-
seminated is not making a contribution.
Failure to publish is not only inappropriate scientific conduct, it
also influences the information available for interpretation by the
scientific community and by clinicians. If research is left randomly
unpublished, there is less information available, but that informa-
tion is not necessarily biased. The tendency for investigators to
submit manuscripts and of editors and reviewers to accept them,
based on the strength and direction of the research findings, has
been defined as publication bias (Chalmers 1990; Dickersin 1990;
Dickersin 1997).
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The validity of a systematic review depends on the methods used
to conduct the review and the ability to identify and include rel-
evant studies. If there is a systematic bias, such that studies with
statistically significant or positive findings are more likely to be
published and included in systematic reviews than trials with non-
significant findings, then the validity of a review’s conclusions may
be threatened.
O B J E C T I V E S
To systematically review studies of cohorts of clinical trials that
investigate the extent to which publication is influenced by the
statistical significance, perceived importance, or direction of trial
results.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Studies were eligible if they assessed a cohort of trials registered at
onset or while ongoing, but prior to the main results being known
(e.g. trials entered into a formal database, or submitted to an ethics
committee or a prospective trials register).
Types of data
Eligible studies included either a complete series of trials (e.g. all
registered during a specified time period) or an unbiased sample
(e.g. a random sample) of trials in a cohort. Studies were accepted
as clinical trials if they were so defined by the study authors, and
involved the testing of a health care intervention in humans. Stud-
ies that had also included other types of research were eligible for
this review, if data specifically related to clinical trials were avail-
able and could be analysed separately. If these results could not be
separated, attempts were made to obtain the data from the study
investigators.
Types of methods
Eligible studies needed to compare the publication of trials with
positive findings with the publication of those with either nega-
tive or null findings (collectively termed negative findings for the
purposes of this review). Positive findings included (1) trials classi-
fied as having statistically significant results or P < 0.05, (2) when
there was no statistical test done, findings classified by the study
investigator as important or striking, and (3) those findings show-
ing a positive direction of effect as defined by the authors of the
included studies. Negative findings were defined as (1) those that
were not statistically significant or P ≥ 0.05, (2) where there was
no statistical test done, those findings classified by the study in-
vestigator as of moderate or little importance or not striking, and
(3) those findings showing a negative or null direction of effect as
defined by the authors of the included studies.
Types of outcome measures
To be included studies needed to report at least one of the two
primary outcomes: publication or time to publication. Secondary
outcomes included other potential risk factors possibly associated
with failure to publish: source of funding, sample size, number of
clinical centres, investigator rank and sex. If sufficient data were
available we assessed whether or not the study results were written
up, reasons for failure to publish, publication in English versus
other languages, publication in a MEDLINE versus non-MED-
LINE-indexed journal, and publication type (e.g. grey literature,
including in-house publications and theses).
Search methods for identification of studies
We searched theCochraneMethodology Register (Issue 2, 2007 as
published in The Cochrane Library [Online]) using the index term
“publication bias” which includes “language bias” and “duplicate
publication bias”. In addition we searched MEDLINE (1950 to
March Week 2 2007 Appendix 1), EMBASE (1980 to Week 11
2007 Appendix 2 ) and Ovid MEDLINE In-Process & Other Non-
Indexed Citations (March 21 2007 Appendix 3).
We also searched the Science Citation Index (April 2007) to iden-
tify additional articles that cited any included studies. Finally we
contacted authors of key studies on publication bias to try to iden-
tify further studies, and checked reference lists of any included
studies to identify references to possible relevant citations.
Data collection and analysis
Selection of studies
Our searches identified over 5000 references. One author (SH)
screened the titles and abstracts of all retrieved records to identify
obvious exclusions. A second author (KL) checked all retrieved
records once any obvious exclusions had been removed. Any dis-
agreements were resolved through discussion. Each of the non-
rejected records were assessed by at least two authors to see if they
were likely to meet the inclusion criteria and full copies of the re-
ports were obtained. Each of the full reports were then assessed by
at least two authors to determine if they met the inclusion criteria
for the review. Any disagreements were resolved through discus-
sion.
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Data extraction and management
Two authors independently extracted data from each of the in-
cluded studies. Differences in data extraction were resolved by dis-
cussion. We contacted the authors of the studies if information
was either incomplete or missing, or to obtain data separately for
reports of clinical trials.
We extracted the following data when available:
Relationship of publication to positive findings and magnitude of
effect:
• Statistical significance or P value (< 0.05 versus ≥ 0.05)
• Perceived importance of the findings (clinically important,
striking)
• Direction of results (positive or negative)
• Time to publication
Relationship of publication to other potential risk factors:
• Funding mechanism (grant, contract, other)
• Sample size (< 100, 100 to 999, > 999 or as defined in
included studies)
• Number of centres
• Primary investigator (male versus female)
• Primary investigator academic rank (e.g. professor, associate
professor, assistant professor, other)
Outcome measures:
• Publication
• Publication type (e.g. grey literature, abstract, presentation,
language of publication)
Assessment of risk of bias in included studies
The following criteria, perceived as likely sources of bias, were used
to assess the methodological quality of included studies:
1. Was there an inception cohort?
Yes = a sample of clinical trials registered at onset or on a roster
(e.g. approved by an ethics committee) during a specified period
of time
No = anything else
Unclear
2. Was there complete follow up (after data analysis) of all of the
trials in the cohort?
Yes ≥ 90%
No < 90%
Unclear
3. Was publication ascertained through personal contact with the
investigators or sponsor?
Yes = personal contact with investigators or sponsor, or searching
the literature and personal contact with investigator or sponsor
No = searching the literature only
Unclear
4. Were positive and negative findings clearly defined?
Yes = clearly defined
No = not clearly defined
Unclear
5. Were other possible confounders examined in the analysis, for
example: sample size, duration, multi-centre versus single centre,
funding (external versus internal, industry funded versus other),
investigator academic rank orwhether trialswere grouped for com-
mon treatment comparisons?
Yes = two or more of the above.
No = one or none
Unclear
Data synthesis
The primary analysis was to compare publication and time to pub-
lication for trials with positive findings compared to those with
negative or null findings. Studies used slightly different definitions
for positive, negative and null findings and therefore we first anal-
ysed the data separately for studies using similar definitions. No
statistical heterogeneity was observed among studies for the odds
ratio estimate and we proceeded with combining results from the
individual studies to produce an overall pooled effect estimate us-
ing the odds ratio (calculated using the Mantel-Haenszel method)
and a fixed-effect model with 95% confidence intervals using The
Cochrane Collaborations ReviewManager software RevMan 5. In
a sensitivity analysis, we converted the overall odds ratio (OR) and
its 95% confidence interval to a risk ratio (RR) using the following
formula: RR = OR/(1 - (Rc x (1 - OR)), where Rc (the control
group risk) was the median proportion of negative trials that were
published among the included studies. We also examined other
factors potentially associated with publication, including funding
mechanism, sample size, number of centres, and primary investi-
gator rank and sex.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of studies awaiting classification.
Included studies
Five studies (Bardy 1998; Dickersin 1992; Dickersin 1993;
Ioannidis 1998; Stern 1997) met the inclusion criteria and as-
sessed the proportions of published trials in a cohort of clinical
trials. All of the studies were published as full articles in journals.
Studies used slightly different definitions to define trials with posi-
tive findings and trials with negative findings. The study by Bardy
1998 assessed the publication of a cohort of clinical trials notified
to the National Agency for Medicine in Finland (1987). Trials
were classified by the authors as having either positive, negative or
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inconclusive findings (P values were not given). Dickersin 1992
assessed the publication of clinical trials approved by two institu-
tional review boards (IRBs) in 1980 and Dickersin 1993 assessed
the publication of clinical trials funded by the National Institutes
of Health in 1979. In both of these studies, trial findings were clas-
sified by the primary investigator as either statistically significant,
similar, or not statistically significant. When statistical tests were
not used, investigators were asked to classify the findings as im-
portant or not. Ioannidis 1998 assessed the publication of AIDS
trials funded by the National Institutes of Health (1986 to 1996).
Trials were classified as either positive if the P value was < 0.05
or favoured the experimental arm of the trial, or as negative if the
findings were associated with a P value ≥ 0.05 or favoured the
control arm of the trial. Finally, the study by Stern 1997 assessed
the publication of clinical trials approved by a local ethics com-
mittee (1979 to 1988). Trial findings were classified as statistically
significant if the P value was < 0.05, as showing a non-significant
trend if 0.05 < P < 0.10, or as non-significant or null if no differ-
ence was observed between the two groups (see Characteristics of
included studies).
Excluded studies
Ten studies that were initially assessed as potentially eligible were
later excluded from this review (Chan 2004A; Chan 2004B;
Cronin 2004; Decullier 2005; Easterbrook 1991; Hahn 2002;
Misakian 1998;Melander 2003; Pich 2003;Wormald 1997).Nine
studies assessed factors influencing publication in a cohort of stud-
ies such as those approved by an ethics committee or local fund-
ing body. One study assessed factors influencing publication in a
cohort of studies approved by the Swedish Drug Regulatory Au-
thority (Melander 2003). In four studies (Cronin 2004; Decullier
2005; Easterbrook 1991; Misakian 1998) information on the rate
of publication for positive versus negative findings was not avail-
able separately for reports of clinical trials. In three studies (Hahn
2002; Pich 2003; Wormald 1997) the association between pub-
lication and the statistical significance of trial results was not as-
sessed and in two studies (Chan 2004A;Chan2004B) nodatawere
available on trial findings when trials were unpublished. In the
final study (Melander 2003) some trials were registered after the
main results had been published (see Characteristics of excluded
studies).
Ongoing studies
We identified no ongoing studies.
Risk of bias in included studies
We assessed the methodological quality of the included studies
using the criteria described in the Methods section. Full details
of the methodological quality of the included studies are given
in the ’Risk of bias tables’. In two studies (Dickersin 1993; Stern
1997), there was less than 90% follow up of all trials; in the study
by Dickersin 1993 there was 86% follow up and in the study by
Stern 1997 70% follow up. In the other study (Bardy 1998), the
definition of positive and negative findings was unclear, as were
control for possible confounders in the analysis.
Effect of methods
Publication and trial findings
(Table 1)
All five studies (Bardy 1998; Dickersin 1992; Dickersin 1993;
Ioannidis 1998; Stern 1997) assessed the association between pub-
lication and trial findings. The percentage of published clinical
trial findings varied greatly across the five studies and ranged from
93% in the study by Dickersin 1993 of National Institutes of
Health trials, to 36% in the study by Bardy 1998 ofMedicineCon-
trol Agency trials. Trials with positive findings were more likely to
be published than trials with negative or null findings (odds ratio
3.90; 95% confidence interval 2.68 to 5.68) (Analysis 1.1; Figure
1). This corresponds to a risk ratio of 1.78 (95% CI 1.58 to 1.95),
assuming that 41% of negative trials are published (the median
among the included studies, range = 11% to 85%). In absolute
terms, this means that if 41% of negative trials are published, we
would expect that 73% of positive trials would be published. The
risk ratio for each individual study is provided in Analysis 2.1
(Figure 2); individual risk ratios were not pooled due to high levels
of heterogeneity (I2 = 88%; Chi2 = 32.32 (df = 4); P < 0.00001).
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Figure 1. Forest plot of comparison: 1 Rate of publication and significance of trial result (pooled), outcome:
1.1 Total number of trials published.
Figure 2. Forest plot of comparison: 2 Rate of publication and significance of trial result (unpooled),
outcome: 2.1 Total number of trials published.
Only one of the five studies (Dickersin 1993) provided informa-
tion separately for trials on why the investigators had not pub-
lished the trial findings. Some of the reasons were that the trial
results were not interesting or that the investigators had not had
time (43%), that they had co-investigator or other operational
problems (38%), and that they had additional analyses to com-
plete (14%). In some cases, they did not know the reason.
Time to publication and statistical significance or
direction of trial results
(Table 2)
Two studies (Ioannidis 1998; Stern 1997) assessed time to publica-
tion and statistical significance or direction of the trial findings. In
both studies the median time to publication was calculated from
a survival type analysis of all the eligible trials. In the study by
Ioannidis 1998 the median time from start of enrolment to first
publication was 5.5 years. This was less for trials with positive find-
ings (P < 0.05, or as defined by the authors of the studies included
in this review), with a median of 4.3 years as compared to 6.5
years for trials with negative or null findings (Hazard Ratio (HR)
for time to publication for positive versus negative or null findings
3.7; 95% CI 1.8 to 7.7). The median time from completion of
follow up to first publication was 2.4 years, which was shorter for
trials with positive findings with a median of 1.7 years as com-
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pared to 3.0 years for trials with negative or null findings (HR
3.2; 95% CI 1.6 to 6.2). Stern 1997 measured the time interval
between approval by the ethics committee and first publication.
This was less for trials with positive findings with a median of 4.7
years (95% CI 3.8 to 5.7 as compared to 7.9 years for trials with
negative or null findings (95% CI 7.2 - infinity) (HR 4.2; 95%
CI 1.7 to 10.3). Further details on these studies are included in a
Cochrane methodology review of time to publication for clinical
trials (Hopewell 2007B).
Other potential risk factors influencing publication
(Table 3)
A study of trials funded by the National Institutes of Health in
the US (Dickersin 1993) found no significant difference between
funding mechanism and publication (grants: 91% published; con-
tracts: 98% published; other funding: 91% published). Studies
by Stern 1997 and Dickersin 1992 also assessed the association
between publication and source of funding, however, it was not
possible to obtain information separately for clinical trials.
Three studies (Dickersin 1992; Dickersin 1993; Ioannidis 1998)
assessed the associationbetweenpublication and sample size.None
of the studies had a statistically significant association between
sample size and the proportion of trials published. In the study
by Dickersin 1993, 91% of trials with a sample size of less than
100 participants were published compared to 95% of trials with a
sample size of 100 participants or more. In the study by Dickersin
1992 86% of trials with a sample size of less than 100 partici-
pants were published compared to 92% of trials with a sample
size of 100 participants or more. In the study by Ioannidis 1998,
51% of trials with a sample size of less than 200 participants were
published compared to 79% of trials with a sample size of 200 to
1000 participants, and 67% of trials with a sample size of more
than 1000 participants. The study by Stern 1997 also assessed the
association between publication and sample size, however, it was
not possible to obtain information separately for clinical trials.
One study assessed differences in the proportion of trials pub-
lished for multi-site versus single-site trials and found a difference
that was not statistically significant (91% published versus 96%
published, respectively, (Dickersin 1993)).
One study (Dickersin 1993) assessed the association between the
academic rank of the primary investigator and publication. In this
study the differences were not statistically significant between rank
and publication (95% of studies with a professor investigator were
published; 91%with associate or assistant professor; 88% of other
rank were published).
One study (Dickersin 1993) assessed the association between sex
of the primary investigator and publication. It did not find a sta-
tistically significant association between the sex of the primary in-
vestigator and publication (93% for males and 88% for females).
No information was available in the included studies for the fol-
lowing secondary outcome measures: publication in English ver-
sus other languages; publications indexed in MEDLINE versus
non-MEDLINE; and type of publication. However, the study by
Dickersin 1993 showed that 95% of published trials appeared in
MEDLINE-indexed journals.
D I S C U S S I O N
Despite rigorous searches, only five studies assessing the associa-
tion between findings and publication in a cohort of clinical trials
were identified. These studies showed that trials with positive find-
ings are more likely to be published, and published more quickly,
compared to trials with negative findings (odds ratio 3.90; 95%
confidence interval 2.68 to 5.68). These findings support those
of a closely related Cochrane review assessing full publication of
findings initially presented as conference abstracts. Here abstracts
of clinical trials with positive findings were also published more
quickly and more frequently than those with negative findings
(RR 1.18, 95% CI 1.07 to 1.30) (Scherer 2007).
For our primary analysis we used the odds ratio, as planned in
the protocol. In a sensitivity analysis using the risk ratio we found
substantial heterogeneity (I2 = 88%, P < 0.00001) and elected not
to report the overall risk ratio. There was no evidence of hetero-
geneity among the odds ratios (I2 = 0%, P = 0.66). To reduce the
chances of the odds ratio being misinterpreted (as a risk ratio),
we converted the overall odds ratio (OR) and its 95% confidence
interval to a risk ratio, assuming that 41% of negative trials were
published (the median among the included studies) and found
RR 1.78; 95% CI 1.58 to 1.95. It should be noted that the corre-
sponding risk ratio would be larger when a smaller proportion of
negative trials were published and smaller when a larger propor-
tion of negative trials were published. This is consistent with the
findings of the individual studies (Figure 2) and with what would
be expected if the proportion of negative trials that are published
is large (85% at the upper range of the included trials).
Data were available from three of the five studies included in our
review assessing other risk factors potentially associated with fail-
ure to publish. Three showed no statistically significant associa-
tion between sample size and publication and one study found no
statistically significant association between funding mechanism,
investigator academic rank, or sex and publication.
It would have been of interest to know whether positive findings
are associated with abstract publication, publication in the grey
literature, or full publication in indexed journals. However, this
information was not available in the included studies.
Other studies not included in this review have assessed the asso-
ciation between publication and trial findings in a cohort of reg-
istered studies, but the subset of clinical trials was not available
separately (see Characteristics of excluded studies). Attempts have
been made to contact the authors of these studies but the other
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data were either no longer available, or the analysis was not carried
out.
Only one of the five studies provided information specifically for
trials on why the investigators had not published the trial findings.
The most common reasons were because the investigators thought
the trial findings were not interesting enough or had lack of time.
These findings are supported by other studies assessing failure to
publish the results of clinical research; here reasons included that
the authors thought that a journal was unlikely to accept their
study, or because the authors themselves perceived that the results
were not important enough (Callaham 1998; Donaldson 1996;
Easterbrook 1991; Weber 1998).
In an attempt to determine whether there was any evidence of
publication bias occurring after manuscripts were submitted to
a journal and during the editorial process, Olson and colleagues
(Olson 2002) tracked manuscripts submitted to JAMA until their
publication decision. They concluded that there was no statisti-
cally significant difference in the publication rates between studies
with positive and negative results. There was also no difference in
the time frommanuscript submission to publication in the journal
for studies with positive and negative results (Dickersin 2002).
One of the potential limitations of this review is that the trials
included in the studies we have reviewed were undertaken one or
more decades in the past. It is possible that publication practices
may have changed over the last decade which could change the
results of this review, although this is unlikely given the relatively
short time span. Indeed a very recent study of Food and Drug
Administration registered studies suggests that failure to publish
based on the strength and direction of trial findings is still signif-
icant a problem. In this study 97% (n = 37/38) of FDA clinical
trials with positive findings were published compared to 33% (n
= 8/24) of studies with negative findings (Turner 2008). These
findings will be incorporated when this Cochrane review is next
updated and all searches have been rerun systematically.
This review focuses on one very important aspect of publication
bias, that is, publication associated with the trial findings. Other
factors are also associated with failure to publish, for example,
there is evidence to show that published reports of clinical trials
funded by industry are more likely to show positive results than
those trials funded by other sources such as government (Bero
1996; Djulbegovic 2000; Kjaergard 2002; Lexchin 2003). Selec-
tive reporting of trial outcomes within studies is also a substantial
problem, with trialists more likely to report and publish fully out-
come measures that have positive results (Chan 2004A). In con-
trast, there is conflicting evidence as to whether positive findings
are more likely than negative findings to be published in an En-
glish-language journals compared to non-English language jour-
nals (Egger 1997; Jüni 2002).
The findings of this review support the need for review authors to
search for and include trials in both the published and unpublished
literature (Hopewell 2007A) as there is strong evidence to show
that there may be systematic differences in the results of these
trials. One of the problems faced by those carrying out systematic
reviews is how to identify all trials for a particular condition or
health care intervention, irrespective of the statistical significance
or direction of the trial’s results.
Publication bias in health care has been examined over many years
(Dickersin 1987; Simes 1986; Simes 1987). There is general agree-
ment that those who carry out systematic reviews need to identify
as unbiased and complete a set of relevant studies as possible for
inclusion in their review, to minimize biased and misleading re-
sults. Statistical methods for detecting publication bias exist but
their application can be problematic (Song 2000).
Over the last 25 years, there have been repeated calls to register
clinical trials at their inception, to assign unique trial identification
numbers, and to record other basic information about the trial
so that essential details are made publicly available (Tonks 2002).
In September 2004 members of the International Committee of
Medical Journal Editors published a statement saying that they
would only consider a trial for publication if it has been registered
before the enrolment of the first patient (as of 1 July 2005) (De
Angelis 2005). This is an important step forward for the prospec-
tive registration of clinical trials and one which we hope will be
endorsed by other journals. Registration will aid those conducting
systematic reviews as it will help protect against publication bias.
The World Health Organisation is establishing an International
Clinical Trials Registry Platform with the dual aims of improving
access to information about clinical trials and their findings, and
producing a single worldwide standard for information that trial-
ists should disclose (Gulmezoglu 2005).
A U T H O R S ’ C O N C L U S I O N S
Implication for systematic reviews and
evaluations of healthcare
Trials with positive findings are more likely to be published and
published quicker than trials with negative findings. Those carry-
ing out systematic reviews need to ensure they assess the potential
problems of publication bias in their review and consider meth-
ods for addressing this issue by ensuring a comprehensive search
for trials in both the published and unpublished literature. The
prospective registration of all clinical trials at inception and be-
fore their results become available would enable review authors to
know when relevant trials have been conducted, so that they can
ask the responsible investigators for the relevant study data.
Implication for methodological research
This review focuses on one very important aspect of publication
bias, that is, publication associated with the trial findings. A sys-
tematic investigation into other potential risk factors associated
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with publication, such as the selective reporting of outcomeswould
be warranted.
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∗ Indicates the major publication for the study
C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bardy 1998
Methods Clinical drug trials notified to the National Agency for Medicine, Finland in 1987.
Publication status was obtained bywriting to the principal investigator or sponsor of each
trial. AMEDLINE search was conducted (1987 - 1995) to identify relevant publications
Data 188 clinical trials.
Comparisons Publication status of trials with positive findings compared with those with negative
or inconclusive findings. Trials were classified as either positive findings, negative or
inconclusive findings. P values were not given
Outcomes Trials with positive findings were more likely to be published than those with negative
or null findings
Total published = 68/188 (36%)
Positive = 52/111 (47%)
Negative = 5/44 (11%)
Inconclusive = 11/33 (33%)
Notes 274 trialswere identified ofwhich 188were included in the analysis. Reasons for exclusion
were: ongoing (n = 9); suspended (n = 64); not commenced (n = 17)
Risk of bias
Item Authors’ judgement Description
Inception cohort? Yes “The material consisted of clinical trials on
medicinal products notified to theNational
Agency forMedicines in 1987.” (page 147)
Complete follow up of all trials? Yes “With a specific request the status of all but
one trial was reported. Of all the 274 trials,
183 were completed, 9 remained ongoing,
64 were suspended and 17 had not com-
menced.” (page 148)
Publication ascertained through personal
contact with investigators or sponsor?
Yes “The sponsors of non-reported trials were
requested by letter to report the outcome
of specified trials” (page 147) ... “A Med-
line search for 1987-1995 was conducted
to identify any publication based on the tri-
als.” (page 148)
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Bardy 1998 (Continued)
Definition of positive and negative findings
clearly defined?
Unclear “... the terms ”better and inferior“ refer to
the opinion of the investigator, not to the
statistical significance. The expression ”not
clinically significantly different“ also refers
to the opinion of the investigators, not to
robust statistical evaluation of equivalence
or non-inferiority.” (page 148)
Possible confounders controlled for in the
analysis?
Unclear No statistical methods are reported have
been applied in order to control for possi-
ble confounders
Dickersin 1992
Methods Studies submitted and approved by two institutional review boards (IRBs) which serve
the John Hopkins Health Institutions prior to and during 1980. Publication status was
obtained in 1988 by a telephone call to the principal investigator of each study
Data 168 clinical trials.
Comparisons Publication status of studies with significant findings compared with those with non-
significant findings. Studies were classified as either statistically significant if the P value
was < 0.05, or as not significant
When statistical tests were not used, investigators were asked to classify the findings as
”important“ or not
Outcomes Trials with significant findings were more likely to be published than those showing non-
significant findings
Total published = 136/168 (81%)
Significant = 84/96 (87%)
Non significant = 52/72 (72%)
Other variables assessed included sample size, primary funding source, sex and academic
rank
Notes 1048 applications were received by the IRBs of which 514 were included in the analysis.
Reasons for exclusion were: applications withdrawn, not approved, not implemented,
exempt, did not describe a study, or no humans (n = 311); data on both results and pub-
lication not available (n = 223). 273 were observational studies, 73 were experimental
studies and 168 were clinical trials and included data on both study results and publica-
tion
Risk of bias
Item Authors’ judgement Description
Inception cohort? Yes ”The studies that formed the basis for
our research were those that appeared on
the logs of the two institutional review
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Dickersin 1992 (Continued)
boards (IRBS) that serve The Johns Hop-
kinsHealth Institutions and were approved
in 1980 or prior to 1980 and were still on-
going in that year... the logs of the two insti-
tutions ... enumerated 1048 applications.“
(page 374)
Complete follow up of all trials? Yes 1048 applications were received by the
IRBs of which 514 were included in the
analysis. Reasons for exclusion were: ap-
plications withdrawn, not approved, not
implemented, exempt, did not describe a
study, or no humans (n = 311); data on
both results and publication not available
(n = 223). 273 were observational studies,
73 were experimental studies and 168 were
clinical trials
Publication ascertained through personal
contact with investigators or sponsor?
Yes ”The principal investigators associated
with interview eligible studies were con-
tacted for interviews in 1988 ... Publica-
tion status of a study was determined from
responses provided to specific questions
asked during the interview.“ (page 375)
Definition of positive and negative findings
clearly defined?
Yes ”Studies reported to have statistically sig-
nificant findings were combined with those
reported to have findings of great impor-
tance. Together they are referred to as “sig-
nificant” and are contrasted with the re-
minder, which are referred to as “not sig-
nificant”. In this article we chose to use the
term statistically significant to refer to P
value less than 0.05.” (page 375)
Possible confounders controlled for in the
analysis?
Yes “ ... initially, unadjusted ORs for the associ-
ation between variables listed in table 4 and
publication were calculated for each IRB
separately using SAS ... Subsequently, ad-
justed ORs for each IRB alone and for the
two IRBs combined (by including a term in
themodel for the effect of IRB) were calcu-
lated usingmultiple logistic regression. The
combined model included two-way inter-
action terms between IRB and each of the
other factors.” (page 376)
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Dickersin 1993
Methods Completed clinical trials funded by the National Institute of Health (NIH) in 1979
(excluding National Cancer Institute). Publication status was obtained in 1988 by a
telephone call to the principal investigator of each study
Data 198 completed trials funded by the NIH.
Comparisons Publication status of studies with significant findings compared with those with non-
significant findings. Trials were classified by the primary investigator in terms of statistical
significance or classified as not significant
When statistical tests were not used, investigators were asked to classify the findings as
“important” or not
Outcomes Trials with significant findings were more likely to be published than those showing non-
significant findings
Total published = 184/198 (93%)
Significant and published = 121/124 (98%)
Non significant and published = 63/74 (85%)
Other variables assessed included sample size, funding mechanism, sex and academic
rank
Notes 332 clinical trials were funded by the NIH in 1979 of which 198 were included in the
analysis. Reasons for exclusion were: investigator refused to interview (n = 40); not a trial
(n = 22); no patients (n = 17); analysis not completed (n = 55)
Risk of bias
Item Authors’ judgement Description
Inception cohort? Yes “We obtained magnetic tapes of the 1979
Inventory of Clinical Trials from the Na-
tional Institutes of Health. We elected to
follow trials funded by all institutes except
the National Cancer Institute.” (pages 3,4)
Complete follow up of all trials? No 332 clinical trials were funded by the NIH
in 1979 of which 198 were included in the
analysis. Reasons for exclusion were: inves-
tigator refused to interview (n = 40); not a
trial (n = 22); no patients (n = 17); analysis
not completed (n = 55). There was 86% of
follow up
Publication ascertained through personal
contact with investigators or sponsor?
Yes “Investigators were asked whether any ab-
stracts, journal articles, book chapter pro-
ceedings, letters to the editor, or other ma-
terial had been published from the trial.
If there had been, they were asked for the
number of publications and the references.
If there had not been any publications, the
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Dickersin 1993 (Continued)
investigators were asked why not. Publica-
tions were classified by whether or not they
were in journals indexed by the 1988 Index
Medicus.” (page 5)
Definition of positive and negative findings
clearly defined?
Yes “Investigators were also asked to charac-
terize the trial findings, either in terms of
the results of statistical testing or in terms
of the investigator’s assessment of the rela-
tive importance of the results, when statis-
tical tests were not used. For analysis pur-
poses, responses were classified as falling
into 1 of 2 groups: results reported to be
statistically significant in either direction
were grouped with those deemed to be of
”great importance“ and classified as ”sig-
nificant“. Results showing a trend either
direction, but not statistically significant,
were grouped with those results designated
by investigators to be of ”moderate impor-
tance“ with those results showing no differ-
ence, and those designated to be of ”little
importance“. This 2nd group was classified
as having ”non-significant“ results.” (page
4)
Possible confounders controlled for in the
analysis?
Yes “A forward, stepwise logistic regression
procedure,17 BMDP LR (BMDP statisti-
cal software, Los Angeles, 1990), was used
to compute the adjusted OR. The regres-
sion model tested the following variables:
significance of results, funding, multicen-
ter status, number of study groups, sample
size, type of control, use of randomization,
masking, type of analysis, PI rank in 1988,
and PI sex. Missing value were imputed to
the most frequent category.” (page 5)
Ioannidis 1998
Methods Multi-centre trials groups in HIV sponsored by the National Institute of Health (NIH)
conducted between1986 and1996. Publication status was obtained from the trial registry
that sponsored the trial
Data 66 multi-centre AIDS trials.
Comparisons Publication status of trials with positive findings compared with those with negative
findings. Trials were classified as either positive if P < 0.05 (or favoured the experimental
arm of the trial), or as negative if the difference had a P value above 0.05 (or favoured
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Ioannidis 1998 (Continued)
the control arm of the trial)
Outcomes Trials with positive results were more likely to be published than those with negative
results
Total published = 36/66 (54%)
Positive = 20/27 (74%)
Negative = 16/39 (41%)
Other variables assessed included time to publication and sample size
Notes 109 trials were identified of which 66 were included in the analysis. Reasons for exclusion
were: closed as failed to accrue (n = 8); still open to accrual (n = 25); still open to follow
up (n = 10)
Risk of bias
Item Authors’ judgement Description
Inception cohort? Yes ”All efficacy clinical trials conducted from
1986 until 1996 by the AIDS Clinical
Trial Group (ACTG) and by the Terry
Beirn Community Programs for Clinical
Research on AIDS (CPCRA) were consid-
ered in the analysis.“ (page 282)
Complete follow up of all trials? Yes 109 trials were identified of which 66 were
included in the analysis. Reasons for exclu-
sion were: closed as failed to accrue (n = 8)
; still open to accrual (n = 25); still open to
follow up (n = 10) (page 282)
Publication ascertained through personal
contact with investigators or sponsor?
Yes ”Supplemental information about recently
analysed trials and clarifications on unclear
or missing data were obtained from inves-
tigators and medical officers and staff re-
sponsible for the protocols.“ (page 282)
Definition of positive and negative findings
clearly defined?
Yes ”In this article, a trial is called “positive” if a
statistically significant finding (denoted by
P < 0.05) had been found in the analysis of
the data for a main efficacy end point de-
fined in the protocol in favour of an experi-
mental therapy arm. Trials with non statis-
tically significant findings or favouring the
control arm are called “negative ...” (page
282)
Possible confounders controlled for in the
analysis?
Yes “ .. the significance levels of the findings
and other trial characteristics were used as
covariates for the risk of publication in Cox
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Ioannidis 1998 (Continued)
proportional hazard regression. Trial char-
acteristics included the actual sample size,
the ratio of accrual compared with the orig-
inally anticipated (target) enrolment (typi-
cally based on power calculation), the trial-
ist group, the age of the population (adult
or paediatric), the trial domain (antiretro-
viral therapy vs complication of HIV), the
presence or not of double blinding, and the
place were dataweremanaged (pharmaceu-
tical industries or other).” (page 282)
Stern 1997
Methods Studies submitted and approved by the ethics committee of the Royal Alfred Hospital
Sydney between 1979 and 1988. Publication status was obtained in July 1992 by a
telephone call to the principal investigator of each study
Data 130 completed trials.
Comparisons Publication status of trials with significant findings compared with those with non-
significant or null findings. Trials were classified as either significant if P < 0.05, as
showing a non-significant trend if the difference had a P between 0.05 and 0.10, or as
null if no difference was observed between the two groups
Outcomes Trials with significant findings were more likely to be published than those showing null
findings
Total published = 73/130 (56%)
Significant = 55/76 (72%)
Non significant trend = 3/15 (20%)
Null = 15/39 (38%)
Other variables assessed included time to publication, funding and sample size
Notes 748 studies were included by the ethics committee of which 130 were included in the
analysis. Reasons for exclusion were: no response from investigators (n = 228); analysis
not yet begun (n = 199); qualitative studies (n = 103); not clinical trials (n = 88)
Risk of bias
Item Authors’ judgement Description
Inception cohort? Yes “Eligible studies were defined as single
studies approved by the Royal Prince Al-
fred Hospital Ethics Committee between
September 1979 and December 1988 with
more than one patient and with protocol
information available.” (page 642)
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Stern 1997 (Continued)
Complete follow up of all trials? No 748 studies were included by the ethics
committee of which 130 were included in
the analysis. Reasons for exclusion were: no
response from investigators (n = 228); anal-
ysis not yet begun (n = 199); qualitative
studies (n = 103); not clinical trials (n = 88)
. There was 70% of follow up
Publication ascertained through personal
contact with investigators or sponsor?
Yes “In July 1992 the principal investigator for
each study was asked to complete a ques-
tionnaire providing information on the
current status; starting date, closure of re-
cruitment, and finishing date; sample size
reached; the nature of funding (none, phar-
maceutical, government, other (external),
or other (internal)); the rating of scientific
importance of the study; the status and date
of the most recent analysis; the main re-
search questions posed by the study at the
outset; the results for the main research
questions; and the publication status and
date of initial publication as an article in a
peer reviewed journal.” (page 642)
Definition of positive and negative findings
clearly defined?
Yes “For quantitative studies, in which the
main study outcome was assessed by us-
ing statistical methods with tests of signifi-
cance, outcomewas classed as significant (P
< 0.05), as showing a non-significant trend
(0.05 < P < 0.10), or as non-significant or
null (P > 0.10) ... For qualitative studies,
in which the main study outcome was as-
sessed subjectively by the principal inves-
tigator, the study was classed as showing
striking, important and definite, or unim-
portant and negative findings.” (page 642)
Possible confounders controlled for in the
analysis?
Yes “With the exception of the investigator’s
rating of scientific importance of the study,
which we judged to be largely influenced
by study results, all other factors were ex-
amined in a multivariate Cox regression to
determine the relative importance of study
results on time to publication adjusted for
any other significant factors.” (page 642)
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Chan 2004A Assessed factors influencing publication of outcomes in randomised trials approved by the Scientific Committees
for Copenhagen and Frederiksberg,Denmark (1994 -1995).Data for positive and negative findings were available
only for published trials
Chan 2004B Assessed factors influencing publication of outcomes in randomised trials approved by the Canadian Institutes
of Health (1990 -1998). Data for positive and negative findings were available only for published trials
Cronin 2004 Assessed factors influencing publication of outcomes in 101 research studies commissioned by theNorth Thames
Region of the NHS R&DProgramme in the UK (1993 -1998). Data were not available separately for reports of
clinical trials. The analysis of proportion published was also not available for positive and negative/null findings
Decullier 2005 Assessed factors influencingpublication in 649 research protocols approvedbyFrenchResearchEthicsCommittee
(1994). Data were not available separately for reports of clinical trials
Easterbrook 1991 Assessed factors influencing publication in 285 studies approved by the Central Oxford Research Ethics Com-
mittee (1984 -1987). Data were not available separately for reports of clinical trials
Hahn 2002 Assessed factors influencing publication of protocols of studies approved by a local ethics committee. This study
did not assess the rate of publication for positive and negative findings
Melander 2003 Assessed factors influencing publication of 42 clinical trials of selective serotonin reuptake inhibitors approved
by the Swedish Drug Regulatory Authority (1989 -1994). Not all trials were registered prior to the main results
becoming known
Misakian 1998 Assessed factors influencing publication in 84 studies of the effects of passive smoking which were identified
through organisations known to fund such research (1981-1995). Data were not available for reports of clinical
trials
Pich 2003 Assessed factors influencing publication in 166 clinical trials submitted to theHospital Clinic Ethics Committee,
Spain (1997). This study did not assess the rate of publication for positive and negative findings
Wormald 1997 Assessed factors influencing publication in 68 clinical trials registered with the pharmacy of Moorfields Eye
Hospital, London (1963 -1993). Data were not available for the rate of publication for positive and negative
findings
Characteristics of studies awaiting assessment [ordered by study ID]
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Menzel 2007
Methods Clinical trials approved by the Medical Association Westfalen-Lippen Research Ethics Committee, Germany (1996)
Data
Comparisons
Outcomes
Notes This study is published in German.
Turner 2008
Methods Clinical trials approved by the Food and Drug Administration (FDA) of antidepressant agents between 1987 and
2004. Publication status was obtained by contacting the drug sponsor and by conducting electronic searches
Data 74 industry-sponsored trials.
Comparisons Publication status of trials with positive findings compared with those with negative findings
Outcomes Trials with positive results were more likely to be published than those with negative results
Total published = 51/74 (69%)
Positive = 37/38 (97%)
Negative = 8/24 (33%)
Questionable = 6/12 (50%)
Notes
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D A T A A N D A N A L Y S E S
Comparison 1. Rate of publication and significance of trial result (pooled)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total number of trials published 5 750 Odds Ratio (M-H, Fixed, 95% CI) 3.90 [2.68, 5.68]
1.1 Positive versus negative or
null
5 750 Odds Ratio (M-H, Fixed, 95% CI) 3.90 [2.68, 5.68]
Comparison 2. Rate of publication and significance of trial result (unpooled)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total number of trials published 5 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 Positive versus negative or
null
5 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
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Analysis 1.1. Comparison 1 Rate of publication and significance of trial result (pooled), Outcome 1 Total
number of trials published.
Review: Publication bias in clinical trials due to statistical significance or direction of trial results
Comparison: 1 Rate of publication and significance of trial result (pooled)
Outcome: 1 Total number of trials published
Study or subgroup Positive Negative Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Positive versus negative or null
Bardy 1998 52/111 16/77 35.1 % 3.36 [ 1.73, 6.53 ]
Dickersin 1992 84/96 52/72 26.0 % 2.69 [ 1.22, 5.96 ]
Dickersin 1993 121/124 63/74 6.7 % 7.04 [ 1.90, 26.16 ]
Ioannidis 1998 20/27 16/39 11.9 % 4.11 [ 1.41, 11.99 ]
Stern 1997 55/76 18/54 20.3 % 5.24 [ 2.46, 11.17 ]
Total (95% CI) 434 316 100.0 % 3.90 [ 2.68, 5.68 ]
Total events: 332 (Positive), 165 (Negative)
Heterogeneity: Chi2 = 2.40, df = 4 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 7.12 (P < 0.00001)
0.1 0.2 0.5 1 2 5 10
Unpublished Published
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Analysis 2.1. Comparison 2 Rate of publication and significance of trial result (unpooled), Outcome 1 Total
number of trials published.
Review: Publication bias in clinical trials due to statistical significance or direction of trial results
Comparison: 2 Rate of publication and significance of trial result (unpooled)
Outcome: 1 Total number of trials published
Study or subgroup Positive Negative Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Positive versus negative or null
Dickersin 1993 121/124 63/74 1.15 [ 1.04, 1.27 ]
Dickersin 1992 84/96 52/72 1.21 [ 1.03, 1.42 ]
Ioannidis 1998 20/27 16/39 1.81 [ 1.17, 2.80 ]
Stern 1997 55/76 18/54 2.17 [ 1.45, 3.25 ]
Bardy 1998 52/111 16/77 2.25 [ 1.40, 3.64 ]
0.1 0.2 0.5 1 2 5 10
Unpublished Published
A D D I T I O N A L T A B L E S
Table 1. Publication and trial findings
Study ID Total published Positive Negative Null
Bardy 1998 68/188 (36%) 52/111 (47%) 5/44 (11%) 11/33 (33%)
Dickersin 1992 136/168 (81%) 84/96 (87%) 52/72 (72%)
Dickersin 1993 184/198 (94%) 121/124 (98%) 63/74 (85%)
Ioannidis 1998 36/66 (54%) 20/27 (74%) 16/39 (41%)
Stern 1997 73/130 (56%) 55/76 (72%) 3/15 (20%) 15/39 (38%)
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Table 2. Time to publication and significance of results
Study ID Time interval Time to publication Positive Negative
Ioannidis 1998 Enrolment to publication 5.5 years (median) 4.3 years (median) 6.5 years (median)
Ioannidis 1998 Completion to publication 2.4 years (median) 1.7 years (median) 3.0 years (median)
Stern 1997 Ethics committee to publi-
cation
4.69 years (median) 7.9 years (median)
Table 3. Other potential risk factors influencing publication
Study ID Source of funding Sample size Academic rank Sex
Dickersin 1992 < 100 participants = 86%
published (110/128)
≥100 participants = 92%
published (34/37)
Dickersin 1993 Grant = 91% published
(92/101)
Contract = 98% published
(58/59)
Other = 91% published
(34/38)
< 100 participants = 91%
published (76/84)
≥ 100 participants = 95%
published (102/107)
Professor = 95% published
(119/125)
Associate / assistant profes-
sor = 91% published (20/
22)
Other = 88% published
(45/51)
Female = 88% published
(14/16)
Male = 93% published
(170/182)
Ioannidis 1998 < 200 participants = 51%
published
200 - 1000 participants =
79% published
> 1000 participants = 67%
published
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A P P E N D I C E S
Appendix 1. MEDLINE search strategy
We searched MEDLINE (1966 to March Week 2 2007) using OVID with the following terms:
1. Publication Bias/
2. exp Publications/
3. publication$.tw.
4. Publishing/
5. publish$.tw.
6. exp Bias Epidemiology/
7. (bias or biases).tw.
8. or/2-5
9. or/6-7
10. 8 and 9
11. 1 or 10
Appendix 2. EMBASE search strategy
We searched EMBASE (1980 to Week 11 2007) using OVID with the following terms:
1. Publishing/
2. publishing.tw.
3. Publication/
4. publication.tw.
5. (bias or biases).tw.
6. or/1-4
7. 5 and 6
Appendix 3. MEDLINE In-Process and Other Non-Indexed Citations search strategy
We searched MEDLINE In-Process and Other Non-Indexed Citations (March 21 2007) using OVID with the following terms:
1. publication?.tw.
2. publish$.tw.
3. 1 or 2
4. (bias or biases).tw.
5. 3 and 4
6. (publication bias or publication biases).tw.
7. 5 or 6
H I S T O R Y
Protocol first published: Issue 3, 2001
Review first published: Issue 1, 2009
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Date Event Description
27 December 2007 Amended Converted to new review format.
20 February 2007 New citation required and major changes Substantive amendment
C O N T R I B U T I O N S O F A U T H O R S
Sally Hopewell and Kirsty Loudon conducted the searches (with help from Marit Johansen), assessed trials for inclusion, extracted
data, contacted authors for additional information, assessed study quality and wrote the review. Mike Clarke, Andy Oxman and Kay
Dickersin contributed to the development of the protocol and commented on drafts of the review.
D E C L A R A T I O N S O F I N T E R E S T
Kay Dickersin was the primary investigator of two of the included studies.
S O U R C E S O F S U P P O R T
Internal sources
• NHS Research and Development Programme, UK.
• National Institute of Public Health, Norway.
• Johns Hopkins University, USA.
External sources
• No sources of support supplied
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Publication Bias; Clinical Trials as Topic [∗statistics & numerical data]
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